Tekla Life Sciences Investors (NYSE:HQL – Get Rating) saw a significant growth in short interest in December. As of December 30th, there was short interest totalling 23,000 shares, a growth of 62.0% from the December 15th total of 14,200 shares. Based on an average trading volume of 103,200 shares, the days-to-cover ratio is currently 0.2 days.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Stratos Wealth Partners LTD. increased its stake in Tekla Life Sciences Investors by 6.4% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 11,136 shares of the company’s stock worth $158,000 after purchasing an additional 673 shares in the last quarter. Wedbush Securities Inc. boosted its position in Tekla Life Sciences Investors by 6.3% during the 2nd quarter. Wedbush Securities Inc. now owns 13,994 shares of the company’s stock worth $199,000 after acquiring an additional 824 shares during the period. Kingsview Wealth Management LLC boosted its position in Tekla Life Sciences Investors by 2.8% during the 3rd quarter. Kingsview Wealth Management LLC now owns 37,158 shares of the company’s stock worth $508,000 after acquiring an additional 1,008 shares during the period. Eudaimonia Partners LLC boosted its position in Tekla Life Sciences Investors by 12.6% during the 3rd quarter. Eudaimonia Partners LLC now owns 13,242 shares of the company’s stock worth $181,000 after acquiring an additional 1,477 shares during the period. Finally, Atria Wealth Solutions Inc. lifted its holdings in shares of Tekla Life Sciences Investors by 4.7% during the 2nd quarter. Atria Wealth Solutions Inc. now owns 41,890 shares of the company’s stock valued at $596,000 after buying an additional 1,865 shares during the last quarter. 15.95% of the stock is owned by institutional investors and hedge funds.
Tekla Life Sciences Investors Price Performance
HQL stock opened at $14.66 on Friday. The firm has a 50 day simple moving average of $14.68 and a 200-day simple moving average of $14.70. Tekla Life Sciences Investors has a twelve month low of $13.03 and a twelve month high of $18.47.
Tekla Life Sciences Investors Announces Dividend
Tekla Life Sciences Investors Company Profile
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
- Get a free copy of the StockNews.com research report on Tekla Life Sciences Investors (HQL)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Tekla Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekla Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.